The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes

[1]  Andrea E. Holmes,et al.  Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses , 2021, Frontiers in Pharmacology.

[2]  M. Fitzcharles,et al.  Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain , 2021, CNS Drugs.

[3]  Marcus A. Rodriguez,et al.  A systematic review of medical students’ and professionals’ attitudes and knowledge regarding medical cannabis , 2021, Journal of Cannabis Research.

[4]  J. Jarosz,et al.  Polish Physicians’ Perspectives on Medical Cannabis Policy and Educational Needs: Results of An Online Survey , 2021, Journal of clinical medicine.

[5]  R. Buchbinder,et al.  Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials , 2021, BMJ.

[6]  Juan Manuel Orjuela-Rojas,et al.  Medicinal cannabis: knowledge, beliefs, and attitudes of Colombian psychiatrists , 2021, Journal of Cannabis Research.

[7]  J. Søndergaard,et al.  Physicians’ experiences, attitudes, and beliefs towards medical cannabis: a systematic literature review , 2021, BMC Family Practice.

[8]  A. Rashidian,et al.  Improving health and mortality data in Eastern Mediterranean Region countries: implementation of the International Classification of Diseases, 11th Revision (ICD-11). , 2021, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[9]  B. Lutz.  Neurobiology of cannabinoid receptor signaling
 , 2020, Dialogues in clinical neuroscience.

[10]  J. Graves,et al.  Knowledge, Practices, and Attitudes of Washington State Health Care Professionals Regarding Medical Cannabis. , 2020, Cannabis and cannabinoid research.

[11]  P. Tadi,et al.  Drug Enforcement Administration Drug Scheduling , 2020 .

[12]  S. Goyal,et al.  High expectations: The landscape of clinical trials of medical marijuana in oncology. , 2020, Complementary therapies in medicine.

[13]  M. Bhandari,et al.  Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis , 2020, Clinical medicine insights. Arthritis and musculoskeletal disorders.

[14]  A. Schlag.  An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK? , 2020, Medical Cannabis and Cannabinoids.

[15]  I. Arévalo-Rodriguez,et al.  Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews , 2020, BMC Complementary Medicine and Therapies.

[16]  L. Degenhardt,et al.  Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. , 2019, The lancet. Psychiatry.

[17]  U. Volpe,et al.  Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review , 2019, Medicina.

[18]  Judith A. Singleton,et al.  Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis – A systematic review , 2019, PloS one.

[19]  M. Biagi,et al.  Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer , 2018, BioMed research international.

[20]  Hao Hu,et al.  A Comprehensive Map of FDA-Approved Pharmaceutical Products , 2018, Pharmaceutics.

[21]  M. King,et al.  Correction to: Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR) , 2018, Quality of Life Research.

[22]  L. Radbruch,et al.  Cannabis-based medicines for chronic neuropathic pain in adults. , 2018, The Cochrane database of systematic reviews.

[23]  G. M. Allan,et al.  Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. , 2018, Canadian family physician Medecin de famille canadien.

[24]  Jimmy Lee,et al.  A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders , 2017, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[25]  Mary Barna Bridgeman,et al.  Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. , 2017, P & T : a peer-reviewed journal for formulary management.

[26]  M. Van Hout,et al.  Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey , 2017, Harm Reduction Journal.

[27]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[28]  M. Ghatei,et al.  Rimonabant: From RIO to Ban , 2011, Journal of obesity.

[29]  Joseph A Boscarino,et al.  Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. , 2010, Addiction.

[30]  S. Greven,et al.  Cardiovascular events during World Cup soccer. , 2008, The New England journal of medicine.

[31]  Nicholas C. Ide,et al.  Issues in the registration of clinical trials. , 2007, JAMA.

[32]  M. Amar.  Cannabinoids in medicine: A review of their therapeutic potential. , 2006 .

[33]  M. Ben Amar,et al.  Cannabinoids in medicine: A review of their therapeutic potential. , 2006, Journal of ethnopharmacology.